The following are some of the stocks that moved up in after-hours trading on Wednesday.
MacroGenics Inc. (MGNX) has provided an update on its phase II study of its lead drug candidate Vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer, dubbed TAMARACK. Preliminary safety data from TAMARACK suggest that reducing the dose and frequency of Vobramitamab duocarmazine improves its safety and tolerability in men with mCRPC. The preliminary efficacy data and updated safety data is expected to be provided by May 31, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com